# Intravitreal Injection of SeeQ CdSe 655 Alt Nanoparticles for Patients With Degenerative Retinal Diseases

> **NCT04008771** · NA · COMPLETED · sponsor: **2C Tech Corp** · enrollment: 20 (actual)

## Conditions studied

- Retinitis Pigmentosa

## Interventions

- **DEVICE:** SeeQ CdSe 655 ALT

## Key facts

- **NCT ID:** NCT04008771
- **Lead sponsor:** 2C Tech Corp
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-06
- **Primary completion:** 2014-12-19
- **Final completion:** 2014-12-19
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2019-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04008771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04008771, "Intravitreal Injection of SeeQ CdSe 655 Alt Nanoparticles for Patients With Degenerative Retinal Diseases". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04008771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*